NCT05181085View on ClinicalTrials.gov

Study of NST-6179 in Healthy Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

70

Participants

Timeline

Start Date

November 11, 2021

Primary Completion Date

May 27, 2022

Study Completion Date

May 27, 2022

Conditions
Short Bowel SyndromeParenteral Nutrition Associated Liver Disease
Interventions
DRUG

NST 6179

orally administered, fully synthetic medium chain fatty acid (MCFA) analogue

DRUG

Placebo

inactive analogue

Trial Locations (1)

LS2 9LH

Covance Clinical Research Unit, Ltd, Leeds

Sponsors
All Listed Sponsors
lead

NorthSea Therapeutics B.V.

INDUSTRY